Transgene Biotek Share Price

CMP as on03-Dec-20 15:03

₹ 4.55
-0.22 -4.61%

Open

₹ 4.88

Turnover (lac)

₹ 2

Prev. Close

₹ 4.77

Day's Vol (shares)

₹ 75,574

Day's Range

₹ 4.54
₹ 4.88

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 03-Nov-2020 - -
TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2020 ,inter alia, to consider and approve 1) To consider and approve the unaudited standalone & consolidated financial results for the quarter and half year ended on 30th September, 2020 along with the Limited Review Report as provided by the Statutory Auditor of the Company. 2) To change of registered office address from Plot No: 68, 69, 70, 70A, IDA Anrich Industrial Area, Bollaram, Medak Dist - 503325 Telangana India to Plot No: 69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana, India. 3) Any other Matter. At the meeting of the Board of Directors of the company held on 10th November 2020 the following decisions have been taken: 1) Approved the Unaudited Standalone and Consolidated Financial Results alongwith Limited Review Report of the Company for the quarter and Half Year ended on 30th September 2020. 2) Approved the registered office address from Plot No: 68, 69, 70, 70A, IDA Anrich Industrial Area, Bollaram, Medak Dist - 503325 Telangana India to Plot No: 69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana, India. 3) The Board has approved to transfer TrabiORAL technology into its wholly owned subsidiary on terms and conditions approved by the Board of Directors of Transgene Biotek Limited and its subsidary Peroral Bio Private Limited. (As Per BSE Announcement dated on 10.11.2020)
Board Meeting - 13-Aug-2020 - -
TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/08/2020 ,inter alia, to consider and approve 1) To fix date for convening the 30th Annual General Meeting of the Company. 2) To fix the date of book closure. 3) To take on record the unaudited financial results for the quarter ended June 30, 2020. 1) It was decided to hold the 30th Annual General Meeting on Wednesday the 30th September 2020 at IST through Video Conferencing (VC) / Other AudioVisual Means (OAVM). 2) The Register of Members and Share Transfer Books of the Company will remain closed from Saturday the 26th September 2020 to Tuesday the 29th September, 2020 (both days inclusive). 3) Approved the Unaudited Financial Results along with Limited Review Report of the Company for the quarter ended on 30th June, 2020. This is for your information and records. (AS Per BSE Announcement Dated on 24.08.2020)
Board Meeting - 28-May-2020 - -
TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/06/2020 ,inter alia, to consider and approve 1)To consider and approve the Audited Financial Results of the Company for the Quarter and Financial Year ended on 31st March 2020. 2)To consider the Appointment of Ms. Marri Swetha as Independent Additional Director. 3)To discuss and approve Licensing Agreement of TrabiORAL technology with GVK Bio. 1) Ms. Marri Swetha is appointed as an Additional Director (Non-Executive & Independent Director) of the company with effect from 03rd June 2020. 2) The Board has discussed at length on the possibilities and challenges in monetizing TrabiORAL. After detailed deliberations, the Board has approved licensing of TrabiORAL to GVK Bio on terms and conditions of mutual acceptance while retaining the full technology and IP rights with Transgene only. (As Per BSE Announcement Dated on 03.06.2020)
Board Meeting - 25-Feb-2020 - -
TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/03/2020 ,inter alia, to consider and approve 1) To Discuss and approve the Letter of Resignation submitted by Mr.Vikram Polavarupu as Director of the Board and also, as Managing Director of M/s.Transgene Biotek Limited due to health issues. 2) To Discuss and approve setting up of a wholly owned subsidiary of Transgene to faciliate monetization of intellectual assets of the Company, TrabiORAL in particular. 3) To consider, discuss and may recommend for shareholders approval on reclassification of audited balance sheet for the year 2011-12. 1) The Board has accepted the letter of resignation from Mr.Vikram Polavarapu as Managing Director of the Company effective from 04th March 2020. 2) Dr K Koteswara Rao is reappointed as Managing Director of the Company with immediate effect from 04th March 2020. 3)The board has discussed and passed unanimously appropriate resolution for setting up of a wholly owned subsidiary of Transgene to faciliate monetization of intellectual assets of the Company, TrabiORAL in particular. 4) The board has discussed and passed unanimously resolution on reclassification of audited balance sheet for the year 2011-12. This is for kind information and records. (As Per BSE Announcement dated on 04.03.2020)
Board Meeting - 24-Jan-2020 - -
TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2020 ,inter alia, to consider and approve To take on record the unaudited financial results for the quarter ended December 31, 2019. Copies of the Limited Review Reports as submitted by the Statutory Auditors of the company on (Standalone & Consolidated) financial results for the quarter ended 31 st December, 2019 (copy enclosed). (As Per BSE Announcement dated on 04.02.2020)